| |
| |
|
| Insider
Information: |
Crandell Keith |
| Relationship: |
Director, 10% Owner |
| City: |
Chicago |
| State: |
IL |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
14 |
|
| Direct
Shares |
14,726,492 |
|
|
Indirect Shares
|
20,997,912 |
|
|
| Direct
Value |
$338,672,055 |
|
|
|
Indirect Value
|
$429,014,163 |
|
|
| Total
Shares |
35,724,404 |
|
|
| Total
Value |
$767,686,217 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
1
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-1.0
|
0.0
|
| Percentage
Gain/Loss : |
 -35.2%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Illumina Inc |
ILMN |
Former 10% Holder |
2004-02-03 |
6,423 |
2004-02-03 |
2,915,298 |
Premium* |
|
|
Alnylam Pharmaceuticals Inc |
ALNY |
10% Owner |
|
0 |
2004-05-27 |
222,500 |
Premium* |
|
|
Cyclacel Pharmaceuticals Inc |
CYCC |
10% Owner |
2004-03-19 |
0 |
2004-03-19 |
2,054,271 |
Premium* |
|
|
Agios Pharmaceuticals Inc |
AGIO |
10% Owner |
2013-07-29 |
3,860,738 |
2013-07-29 |
0 |
Premium* |
|
|
Adesto Technologies Corp |
IOTS |
Director |
2019-06-04 |
25,396 |
2015-10-30 |
2,276,511 |
Premium* |
|
|
Xtera Communications, Inc. |
XCOM |
10% Owner |
|
0 |
2015-11-17 |
1,885,090 |
Premium* |
|
|
Phaserx, Inc. |
PZRX |
10% Owner |
2016-05-23 |
10,048 |
2016-05-23 |
2,854,222 |
Premium* |
|
|
Sienna Biopharmaceuticals, Inc. |
SNNA |
10% Owner |
2017-08-01 |
0 |
2017-08-01 |
882,493 |
Premium* |
|
|
Quanterix Corp |
QTRX |
|
2023-01-03 |
130,066 |
2021-11-18 |
0 |
Premium* |
|
|
Twist Bioscience Corp |
TWST |
|
2024-02-06 |
18,004 |
2022-02-08 |
76,047 |
Premium* |
|
|
Denali Therapeutics Inc. |
DNLI |
10% Owner |
2019-08-08 |
10,668,749 |
2019-08-08 |
0 |
Premium* |
|
|
Karuna Therapeutics, Inc. |
KRTX |
10% Owner |
2021-04-13 |
918 |
2021-04-13 |
1,456,435 |
Premium* |
|
|
908 Devices Inc. |
MASS |
|
2023-06-14 |
6,150 |
2023-06-14 |
5,725,045 |
Premium* |
|
|
Da32 Life Science Tech Acquisiti... |
DALS |
Director, 10% Owner |
2021-07-30 |
0 |
2023-07-28 |
650,000 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
102 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 5
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AGIO |
Agios Pharmaceuticals Inc |
10% Owner |
– – • |
2013-07-29 |
4 |
A |
$0.00 |
$0 |
D/D |
3,860,738 |
3,860,738 |
0 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
10% Owner |
– – • |
2004-05-27 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
222,500 |
|
- |
|
| CYCC |
Cyclacel Pharmaceuticals ... |
10% Owner |
– – • |
2004-03-19 |
4 |
B |
$8.00 |
$1,500,000 |
I/I |
187,500 |
2,054,271 |
1.5 |
- |
|
| CYCC |
Cyclacel Pharmaceuticals ... |
10% Owner |
– – • |
2004-03-19 |
4 |
A |
$0.00 |
$0 |
I/I |
1,866,771 |
1,866,771 |
|
- |
|
| DALS |
Da32 Life Science Tech Ac... |
Director |
– • • |
2021-07-30 |
4 |
A |
$10.00 |
$6,500,000 |
I/I |
650,000 |
2,250,000 |
0 |
- |
|
| DALS |
Da32 Life Science Tech Ac... |
Director |
– • • |
2021-07-30 |
4 |
B |
$10.00 |
$16,000,000 |
I/I |
1,600,000 |
1,600,000 |
2.25 |
- |
|
| DALS |
Da32 Life Science Tech Ac... |
Director |
– • • |
2023-07-28 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,600,000) |
0 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
10% Owner |
– – • |
2019-08-08 |
4 |
D |
$0.00 |
$0 |
D/D |
(400,000) |
10,668,749 |
0 |
- |
|
| ILMN |
Illumina Inc |
10% Owner |
– – • |
2003-11-26 |
4 |
A |
$0.00 |
$0 |
D/D |
770 |
5,395 |
|
- |
|
| ILMN |
Illumina Inc |
10% Owner |
– – • |
2003-11-26 |
4 |
D |
$0.00 |
$0 |
I/I |
(300,001) |
3,315,298 |
|
- |
|
| ILMN |
Illumina Inc |
Former 10% Holder |
– – – |
2004-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,028 |
6,423 |
|
- |
|
| ILMN |
Illumina Inc |
Former 10% Holder |
– – – |
2004-02-03 |
4 |
D |
$0.00 |
$0 |
I/I |
(400,000) |
2,915,298 |
|
- |
|
| IOTS |
Adesto Technologies Corp |
Director |
– • • |
2015-10-26 |
4 |
B |
$5.00 |
$2,000,000 |
I/I |
400,000 |
400,000 |
2.25 |
- |
|
| IOTS |
Adesto Technologies Corp |
Director |
– • • |
2015-10-30 |
4 |
A |
$0.00 |
$0 |
I/I |
1,876,511 |
2,276,511 |
0 |
- |
|
| IOTS |
Adesto Technologies Corp |
Director |
– • • |
2017-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
6,250 |
14,491 |
0 |
- |
|
| IOTS |
Adesto Technologies Corp |
Director |
– • • |
2017-06-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,241 |
8,241 |
0 |
- |
|
| IOTS |
Adesto Technologies Corp |
|
• • • |
2018-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
3,243 |
17,734 |
0 |
- |
|
| IOTS |
Adesto Technologies Corp |
Director |
– • – |
2019-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
7,662 |
25,396 |
0 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
10% Owner |
– – • |
2020-11-12 |
4 |
D |
$0.00 |
$0 |
I/I |
(150,000) |
1,606,435 |
0 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
10% Owner |
– – • |
2020-11-12 |
4 |
A |
$0.00 |
$0 |
D/D |
1,264 |
306 |
0 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
10% Owner |
– – • |
2021-01-08 |
4 |
D |
$0.00 |
$0 |
I/I |
(150,000) |
1,531,435 |
0 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
10% Owner |
– – • |
2021-01-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,264 |
612 |
0 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
10% Owner |
– – • |
2021-04-13 |
4 |
A |
$0.00 |
$0 |
D/D |
1,264 |
918 |
0 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
10% Owner |
– – • |
2021-04-13 |
4 |
D |
$0.00 |
$0 |
I/I |
(150,000) |
1,456,435 |
0 |
- |
|
| MASS |
908 Devices Inc. |
Director |
– • • |
2020-12-22 |
4 |
B |
$20.00 |
$6,000,000 |
I/I |
300,000 |
5,725,045 |
2.25 |
% |
|
102 Records found
|
|
Page 1 of 5 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
